众生药业(002317.SZ)：正稳步推进昂拉地韦片的商业化工作

Core Viewpoint - The company is closely monitoring disease dynamics and is steadily advancing the commercialization of Anglatide tablets to benefit more patients as soon as possible [1] Group 1 - The company is actively engaged in the commercialization efforts of Anglatide tablets [1] - The company aims to provide benefits to a larger patient population through its ongoing initiatives [1]